```html

Uraemia‑Induced Pericarditis: A Comprehensive Patient Guide

Overview

Uraemia‑induced pericarditis (also called uremic pericarditis) is inflammation of the pericardial sac that surrounds the heart, caused by the accumulation of toxic waste products (uremic toxins) that the kidneys can no longer eliminate. It is a serious extra‑renal manifestation of advanced chronic kidney disease (CKD) or end‑stage renal disease (ESRD).

• Who it affects: Adults with CKD stage 4–5, patients on long‑term dialysis, or those with severe acute kidney injury (AKI). It is rare in children.
• Prevalence: Historically, 5‑10 % of patients on maintenance hemodialysis develop uremic pericarditis, but the rate has fallen to < 2 % in centers that start dialysis early and use modern biocompatible membranes (U.S. Renal Data System, 2022).
• Why it matters: If untreated, the inflamed pericardium can accumulate fluid (pericardial effusion) that may evolve into cardiac tamponade, a life‑threatening emergency.

Understanding the signs, causes, and treatment options helps patients and caregivers act quickly and reduce complications.

Symptoms

Symptoms may develop gradually over days to weeks, or they can appear suddenly after a precipitous rise in urea levels. Common features include:

• Chest pain – sharp, stabbing, or tearing pain that:
  • Worsens with deep inspiration or coughing (pleuritic quality).
  • Improves when sitting up and leaning forward.
• Fever – low‑grade (often <38 °C/100.4 °F) without an obvious source.
• Friction rub – a scratching, squeaky sound heard with a stethoscope over the left lower sternal border; it may disappear as fluid builds up.
• Dyspnea – shortness of breath on exertion, or at rest if effusion is large.
• Palpitations or feeling “fast‑paced” – due to tachycardia or irregular rhythm.
• Peripheral edema – swelling of the ankles/feet, often from concurrent fluid overload in CKD.
• Fatigue, weakness, or malaise – non‑specific but common in uremia.
• Hypotension – especially if tamponade develops; patients may feel dizzy or faint.
• Syncope or near‑syncope – a red‑flag for cardiac tamponade.

Because many of these signs overlap with other cardiac or pulmonary problems, a thorough evaluation is essential.

Causes and Risk Factors

Pathophysiology

Uraemic toxins (e.g., guanidines, phenols, and indoles) stimulate inflammatory cascades in the pericardium. The resulting vasodilation, increased vascular permeability, and infiltration of leukocytes produce the classic pericardial inflammation and effusion. In parallel, volume overload and hyper‑phosphatemia can exacerbate fluid accumulation.

Primary Causes

• Advanced CKD (eGFR < 15 mL/min/1.73 m²) or ESRD.
• Acute kidney injury with rapid rise in BUN/creatinine.
• Inadequate dialysis (missed sessions, low urea clearance).
• Use of non‑biocompatible dialysis membranes that provoke inflammation.

Risk Factors

• Duration of dialysis > 6 months without adequate clearance.
• High pre‑dialysis BUN (> 80 mg/dL) or serum urea nitrogen.
• Concurrent infections (peritonitis, pneumonia) that increase systemic inflammation.
• Hypoalbuminemia (< 3.0 g/dL) – reflects poor nutritional status.
• Rapid fluid shifts (e.g., aggressive ultrafiltration).
• Older age (≥ 65 years) and presence of cardiovascular disease.

Diagnosis

Diagnosis combines clinical suspicion with targeted investigations.

Step‑by‑step approach

1. History & physical exam – Look for chest pain pattern, friction rub, and signs of fluid overload.
2. Electrocardiogram (ECG) – Classic findings include diffuse ST‑segment elevation and PR‑segment depression in multiple leads; however, only ~30 % of uremic pericarditis patients display these changes.
3. Echocardiography – First‑line imaging:
   • Detects pericardial effusion (quantified as small, moderate, or large).
   • Assesses for cardiac tamponade (right‑atrial or right‑ventricular diastolic collapse, respiratory variation in mitral inflow).
4. Chest X‑ray – May show an enlarged, “water‑bottle” silhouette if effusion is large.
5. Laboratory studies:
   • Renal panel – BUN, creatinine, eGFR.
   • Inflammatory markers – ESR, CRP (often elevated).
   • Complete blood count – may reveal anemia of chronic disease.
   • Serum electrolytes – hyper‑phosphatemia, calcium‑phosphate product > 70 mg²/dL increases risk.
6. Pericardial fluid analysis (rare) – Only if effusion is large or diagnosis uncertain; fluid is typically serous, sterile, and low in protein.

Diagnostic criteria (simplified)

Uraemia‑induced pericarditis is diagnosed when all of the following are present:

• CKD stage 4–5 or recent AKI with markedly elevated BUN/creatinine.
• Clinical signs of pericarditis (chest pain, friction rub, ECG changes).
• Evidence of pericardial effusion on echo.
• Absence of alternative causes (e.g., bacterial infection, autoimmune disease, myocardial infarction).

Treatment Options

Treatment aims to eliminate the inciting uremic toxins, control inflammation, and prevent/treat fluid accumulation.

1. Optimizing Renal Replacement Therapy

• Intensified hemodialysis – Most effective; a 4‑hour high‑flux session performed daily for 2‑3 days often resolves symptoms.
• Peritoneal dialysis – Can be used if hemodialysis unavailable, but less efficient at clearing large uremic toxins.
• Continuous renal replacement therapy (CRRT) – Reserved for critically ill patients with hemodynamic instability.

2. Anti‑inflammatory Medications

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – Generally avoided in CKD due to nephrotoxicity and risk of worsening fluid overload.
• Corticosteroids – Low‑dose prednisone (0.5 mg/kg) may be used when dialysis alone does not control inflammation, but long‑term use carries infection and bone loss risks.

3. Pericardial Fluid Management

• Therapeutic pericardiocentesis – Indicated for large effusions causing tamponade or hemodynamic compromise.
• Surgical pericardial window – Considered for recurrent effusions or when pericardiocentesis is unsuccessful.

4. Adjunctive Measures

• Fluid restriction (e.g., <1.5 L/day) to reduce overload.
• Phosphate binders and dietary control to lower calcium‑phosphate product.
• Correction of anemia with erythropoiesis‑stimulating agents (ESAs) to improve oxygen delivery.
• Vaccinations (influenza, pneumococcal, COVID‑19) to decrease infection‑driven inflammation.

5. Lifestyle Modifications

• Adherence to dialysis schedule; never skip treatments.
• Low‑sodium diet (≤ 2 g/day) to limit fluid retention.
• Regular physical activity within tolerance (e.g., walking, stationary cycling) to improve cardiovascular fitness.
• Smoking cessation – smoking accelerates atherosclerosis and pericardial inflammation.

Living with Uraemia‑Induced Pericarditis

Daily Management Tips

• Track symptoms – Keep a diary of chest pain, shortness of breath, or changes in weight (≥ 2 lb in 24 h may indicate fluid gain).
• Monitor blood pressure – Hypertension is common; aim for <130/80 mmHg unless otherwise directed by your nephrologist.
• Weight checks – Weigh yourself daily after voiding; report rapid gains to your care team.
• Medication adherence – Use a pillbox or smartphone reminder for phosphate binders, ESAs, antihypertensives, and any steroids.
• Dialysis access care – Inspect fistula or catheter site for redness or discharge; infection can precipitate pericardial inflammation.
• Nutrition – Work with a renal dietitian to balance protein (0.8–1.0 g/kg/day), limit potassium, phosphorus, and sodium.
• Emotional health – Chronic kidney disease and cardiac complications can cause anxiety. Consider counseling, support groups, or mindfulness training.

Follow‑up Schedule

After an episode, most clinicians recommend:

• Weekly clinical review for the first month.
• Echocardiogram at 2 weeks and again at 6 weeks to confirm resolution of effusion.
• Regular labs (BUN, creatinine, electrolytes, CRP) every 1–2 weeks during the acute phase, then monthly once stable.

Prevention

Proactive management of kidney disease dramatically lowers the risk of uremic pericarditis.

• Early referral to nephrology – Initiate dialysis before BUN exceeds ~70 mg/dL.
• Use high‑flux, biocompatible dialysis membranes – Reduce inflammatory cytokine activation.
• Maintain optimal fluid balance – Restrict sodium, avoid excessive IV fluids during hospital stays.
• Control phosphate – Aim for serum phosphate 3.5–5.5 mg/dL; use sevelamer or calcium‑based binders as prescribed.
• Vaccinate – Protect against infections that can trigger systemic inflammation.
• Regular cardiac screening – Annual ECG and echo for patients with > 5 years on dialysis.

Complications

If left untreated, uremic pericarditis can evolve into serious, sometimes fatal, conditions:

• Cardiac tamponade – Fluid pressure impairs ventricular filling, leading to shock and death.
• Constrictive pericarditis – Chronic inflammation causes scarring and loss of pericardial elasticity, resulting in persistent heart failure.
• Arrhythmias – Inflammation can provoke atrial fibrillation or ventricular ectopy.
• Progressive heart failure – Ongoing pericardial irritation worsens left ventricular ejection fraction.
• Infection – Pericardiocentesis or surgical windows may become infected, especially in immunocompromised dialysis patients.

When to Seek Emergency Care

These signs may indicate cardiac tamponade or a rapidly worsening pericardial effusion, both of which require immediate intervention.

---

Sources: Mayo Clinic, “Uremic pericarditis”; National Kidney Foundation, 2023 Clinical Practice Guidelines; U.S. Renal Data System Annual Report 2022; Cleveland Clinic, “Pericardial Disease”; CDC, “Chronic Kidney Disease in the United States” 2022; WHO, “Kidney Health” 2021; peer‑reviewed articles in Kidney International and Circulation.

```